Here's your news in brief: It was by far the US Food and Drug Administration's busiest week of the year for novel drug approvals with five such products getting the green light from the agency: Genentech Inc.'s Rozlytrek (entrectinib), Celgene Corp.'s Inrebic (fedratinib), the Global Alliance for TB Drug Development's pretomanid, Harmony Biosciences LLC’s Wakix (pitolisant) and AbbVie Inc.’s Rinvoq (upadacitinib).
The Center for Drug Evaluation and Research's novel drug approval count has now jumped to 23 for the year.






